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Histopathology of restenosis
Knowledge on the histopathology of restenosis is
scarce. This indicates that, despite its frequent
occurrence, restenosis after coronary angioplasty is
rarely a lethal disease. Animal models provide some
information on what might occur after angioplasty.
However, the results of these studies should only
be applied to the situation in the atherosclerotic
human artery with great caution.
Steele et al. described the stages of healing and
restenosis in carotid arteries of pigs receiving no
medication'11. One hour after balloon angioplasty,
endothelial denudation, medial tears and platelet
deposition were found. One day later, there was
necrosis of smooth muscle cells. A week later, the
endothelium had completely regrown. About a
month later, there was mild proliferation of smooth-
muscle cells. Significant restenoses, however, were
due to organized intraluminal thrombi.
Waller et al. reported on necropsies in three
patients who died 80 to 150 days after coronary
angioplasty*21. Only one of these patients showed
clinical evidence of recurrence, but all showed sig-
nificant stenoses at the presumed site of antioplasty.
The lesions were not discernible from genuine
atherosclerotic plaques and there was no evidence
of healed dissection.
More in keeping with the current understanding
of the mechanism of balloon angioplasty is a case
report by Essed et al. on a patient who died at the
beginning of a redilatation attempt 5 months after a
successful angioplasty with recurrence of symptoms
at 3 months'3'. These authors found medial dissec-
tion with a narrowing of the new channel by
fibrocellular tissue.
Coronary restenosis: a new disease entity
Restenosis was rapidly recognized as one of the
major problems with coronary angioplasty. It is
now a well known disease entity accounting for
numerous hospitalizations and interventions.
The restenosis rate of the first 169 consecutive
patients treated by Gruentzig in Zurich was 25%
after a mean of 18 months'41.
In 1982, Balcon et al. published a restenosis rate of
67% 3 months after the six successful ahgioplasties
in their first 11 patients'51. With the benefit of angio-
plasty 3 months after the intervention in only two
of 11 patients, their lack of enthusiasm for this
treatment was understandable.
At the same time, the PTCA Registry of the
National Heart, Lung, and Blood Institute
(NHLB1) of the United States reported a clinical
recurrence rate, after a mean of 12 months, of 17%
in 232 patients treated at 34 different centres'61.
In 1983, Meyer et al. reported a recurrence rate of
21 % in 100 consecutive patients after an average of
6 months'71. Their patients were fully anticoagulated
with coumadin. The recurrence rate of patients with
unstable angina was higher than that of patients
with stable angina (24% vs. 17%).
In 1984, Meier et al. reported, from Atlanta,
a recurrence rate of 33% in 514 consecutive
patients"1. The recurrences were documented at a
mean of 5 months (range 1-9 months) after angio-
plasty. Most of the patients were treated with
acetylsalicylic acid. Male sex and stenoses in the left
anterior descending coronary artery (LAD) were
identified as risk factors for restenosis. Figure 1
provides the details of the long-term outcome and
management of these patients.
Another report from the PTCA Registry of
NHLBI on 665 patients followed for 6 months indi-
cated an angiographic recurrence rate of 34% that
correlated well with clinical symptoms'91.
In 1985, Bertrand et al. reported a recurrence rate
of 27% in 269 patients followed for an average of 6
months"01. In the same year the PTCA Registry of
the NHLBI confirmed male sex as a risk factor for
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Figure 1 Follow-up for about I year of 514 consecutive patients with successful
coronary angioplasty at Emory University in Atlanta, Georgia, U.S.A.
recurrence in the 3079 patients included up to that
time1"1. The global recurrence rate was again calcu-
lated at 33%. In men it was 36% and in women it
was22%(/><001).
Kaltenbach et alP] and Kober et a/."3' reported
the recurrence rates of the first 356 and 1000
patients in Frankfurt, respectively. The recurrence
rate was about 15% for both initial patients fol-
lowed for 6 months and for later patients followed
for roughly 12 months. Virtually all the recurrences
occurred within the first 3 months after angioplasty.
They attributed their remarkably low recurrence
rate to stringent adherence to a powerful follow-up
regimen including high daily doses of acetylsalicylic
acid (1-5 g), isosorbide dinitrate (120 mg), and
verapamil (240-480 mg) or gallopamil (100 mg).
A third report from Atlanta on 1880 patients
followed over an average of 7 months revealed a
recurrence rate of 28%[M1. The presence of a visible
local dissection after angioplasty in conjunction
with a residual pressure gradient of < 15 mmHg
identified a favourable subgroup with a recurrence
rate of only 19%.
Mabin et al. reported a recurrence rate of 33%
from the Mayo Clinic in 229 patients followed for a
mean of 13 months'151. In patients with symptoms at
the time of the follow-up examination, restenosis
was present in 71%. In those without symptoms,
restenosis was found in only 14%
Table 1 summarizes the restenosis rates of some
of the cited reports.
Recurrence in mulfHesion angioplasty or moltivessel
angioplasty
Assuming an independent restenosis rate of
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Table 1 Reported recurrence rates of coronary angioplasty (in chronological order)
First author
(place)
Gruentzig
(Zurich)
Kent
(NHLBI Reg.)
Meyer
(Aachen)
Meier
(Atlanta)
Holmes
(NHLBI Reg.)
Bertrand
(Lille)
Cowley
(NHLBI Reg.)
Kaltenbach
(Frankfurt)
Kober
(Frankfurt)
Leimgruber
(Atlanta)
Mabin
(Rochester)
Total
Year
1982
1982
1983
1984
1984
1985
1985
1985
1985
1985
1985
Ref.
[4]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
Number of
patients
169
232
100
514
665
269
3079
356
1000
1880
229
8493
Follow-up
(months)
18
12
6
10
6
6
18
6
12
7
13
Recurrence
rate
25%
17%
21%
33%
34%
27%
33%
12-17%
15%
28%
33%
28%
Remarks
Including first patient
Clinical data only
Unstable 24%, stable 17%;
anticoagulated with coumadin
Higher in men and LAD
acetylsalicylic acid, nifedipine
With symptoms 56%;
without symptoms 14%
Men 36%, women 22%
Repeat PTCA 33%, grafts 45%
salicylate, nitrate, calcium blockers
None after 3 months
Less with dissection and
residual gradient of ^ 15 mmHg
With symptoms 71%;
without symptoms 14%
Table 2 Theoretical recurrence rates in multilesion angio-
plasty (assumed recurrence rate per lesion: 33%)
Number
oflesions Recurrence rate per patient
33%
56%
70%
80%
87%
1/3
5/9
19/27
65/81
211/243
(3 x 3 " " ' - 2 x 2""')/3" x 100%
33% per lesion, the theoretical patient recurrence
rate (recurrence in > 1 stenosis) in double lesion
angioplasty (in 1 or 2 vessels) would be 56%. The
formula used for this calculation and the respective
recurrence rates for multiple lesion angjoplasties
are indicated in Table 2.
Hollman et al. reported a recurrence rate in
single-vessel angioplasty of 38% and in multivessel
angioplasty of 68%(l6]. His findings concur with the
expected recurrence rates and demonstrate that
recurrence is a lesion-related phenomenon rather
than a patient-related phenomenon. These figures
should not be confused with follow-up data on
patients with multivessel disease in whom angio-
plasty is done in one artery only1'71.
Quantitative studies on restenosis
Fleck et al. reported on computer-assisted
analysis of angiograms in 95 patients with follow-up
angiography1181. These authors manually traced two
orthogonal views of the stenosis before and after
angioplasty and again at follow-up. The catheter
was used as calibration reference and the cross-
sectional area of the stenosis was indicated in mm2.
Their definition for restenosis was a loss of ^ 1 mm2
of the cross-sectional area resulting in a > 70%
narrowing of the cross-section. The restenosis rate
was 33%. It correlated well with subjective
symptoms and stress-test data.
Johnson et al. compared a similar computer-
assisted method for evaluating coronary stenoses
with videodensitometry in 23 patients re-examined
after coronary angioplasty1"1. The recurrence rate
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was 35%. The two methods correlated fairly well
(r = 0-77).
Non-invasive detection of resteuosis
Several non-invasive tests have been advocated
for follow-up after coronary angioplasty. Bicycle
exercise tests proved valid in documenting restenosis
in the original patients of Gruentzig1201. Treadmill
exercise tests combined with thallium-201 scintigra-
phy detected six out of nine recurrences in a study
from the Montreal Heart Institute1211.
Wijns et al. analyzed the predictive values of
stress test and thallium-201 scintigraphy performed
1 month after angioplasty in relation to clinical and
angiographic findings at 6 months'22'. For angina,
the predicitive values of stress test and thallium-201
scintigraphy were 38% and 66% and for restenosis
50% and 74%, respectively (/><0O05 in favour of
thallium-201 scintigraphy).
DePuey et al. found a similar predicitive value for
restenosis (73%) with exercise radionuclide ventri-
culography performed shortly after angioplasty1231.
At the time of follow-up angiography, the predictive
value of the same test was 75%.
Restenosis and drugs
In rabbits, both a combination of acetylsalicylic
acid with dipyridamole and sulphinpyrazone sig-
nificantly decreased the extent of restenosis 4
months after iliac ballon angioplasty1241.
A randomized study from Atlanta compared a
daily dose of 325 mg acetylsalicylic acid with anti-
coagulation with coumadin1251. Restenosis was
slightly less frequent in patients treated with acetyl-
salicylic acid. However, statistical significance was
only attained for patients in whom symptoms
occurred >6 months before angioplasty where
retensosis rates were 21% for acetylsalicylic acid
and 44% for coumadin. The compliance in the
coumadin group was rather poor and therapuetic
prothrombin times were only documented in about
one third of these patients.
Two calcium antagonists have been studied in
randomized trials. Both failed to prove efficacious in
preventing or significantly diminishing restenosis.
Diltiazem, as an adjunct to a combination of acetyl-
salicylic acid and dipyridamole, did not reduce
recurrence rate significantly in a study on 92
patients followed for 10 months at the Montreal
Heart Institute1261. The recurrence rate was 15%
with diltiazem and 22% without. Nifedipine was
Table 3 Riskfactorsfor restenosis after coronary angioplasty
Male sex
Diabetes mellitus
Recent angina
Unstable angina
Variant angina
Stenosis in LAD
Stenosis in venous bypass graft
High initial degree of stenosis
High residual degree of stenosis
High residual pressure gradient
Absence of dissection after angioplasty
Ref.
[9,11]
[9,16]
[28]
[7,9,28]
[29]
[8,16]
[9,12]
[16]
[28]
[14]
[14,16]
Coumadin therapy in stenoses older
than 6 months
Interruption of therapy with
acetylsalicyclic acid
[25]
[18]
examined as an adjunct to acetylsalicylic acid in a
double-blind protocol on 241 patients followed for
4 months in Atlanta1271. The restenosis rate was
similar in patients receiving nifedipine (29%) and in
patients receiving a placebo (33%).
Risk factors for restenosis
The risk factors for restenosis identified so far are
listed in Table 3. The following risk factors were
documented in at least two independent studies:
male sex, diabetes mellitus, stenosis in the left
anterior descending coronary artery or in a venous
bypass graft, and absence of intimal dissection after
angioplasty.
The conclusion from a study done in Munich1'81
that the discontinuation of acetylsalicylic acid is a
risk factor for the development of restenosis may be
challenged. Acetylsalicylic acid was discontinued
for gastric pain in all cases concerned and, there-
fore, these symptoms may already have been an
expression of recurrent coronary stenosis.
It must be admitted that currently there is no
proved and practicable method for reducing the
recurrence rate after coronary angioplasty.
Summary
The average restenosis rate reported so far in the
literature is just below 30%. Although restenosis
correlates well with the recurrence of symptoms,
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the two factors are not identical. The incidence of
myocardial infarction during the first 2 years after
coronary angioplasty is 4% and the incidence of
death is 2%1301. These two cardiac events are rarely
the first symptom of restenosis. Restenosis, there-
fore, is not primarily a life threatening disease but
still deserves prompt evaluation and correction.
Restenosis is stenosis-related rather than patient-
related. Thus, restenosis rate per patient increases
with the number of lesions or arteries treated.
Restenosis rates vary considerably with centres.
Serial analyses of restenosis rates at individual
centres revealed that the restenosis rates remained
constant at a centre-specific level. Differences in
case selection and particularities in data definition
and analysis may account for both these obser-
vations. There is no sound evidence that procedural
factors (ballon size, number, duration, or pressure
of inflations, etc.) or drug regimens are capable of
reducing the recurrence rate. All risk factors for
restenosis identified so far are difficult to influence.
Extinguishable factors such as smoking seem of
little importance in this particular problem.
Efforts to find ways of reducing restenoses after
coronary angioplasty are commendable and necess-
ary. Their chance of success, however, is small. 'Old
customers' will continue to represent 20-30% of the
clientele for coronary angioplasty. Their risk for
failure and complications is small, but they do carry
a considerable risk of restenosis.
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